Trial Profile
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARIEL4
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 17 Feb 2023 Status changed from active, no longer recruiting to completed.
- 02 Feb 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 15 Oct 2022 This trial has been completed in Hungary (Date of the global end of the trial : 16-Sep-2022), according to European Clinical Trials Database record.